United Kingdom tests if COVID-19 vaccines might work better inhaled

Henrietta Brewer
September 16, 2020

Phase two trials are created to test which dose and schedule of a vaccine generates the most antibodies while phase three tests the vaccine's efficacy.

British scientists are beginning a small study comparing how two experimental coronavirus vaccines might work when they are inhaled by people instead of being injected.

Chung said the government would negotiate with relevant global organisations and vaccine makers to secure the supply and would buy more as developments unfolded.

Worrisome adverse events haven't appeared so far, but fatigue has been the most common side effect noticed during the trials so far, as per the company presentation.

Over 12,000 study participants had received a second dose of the vaccine, Pfizer executives said on an investor conference call.


The next most commonly reported symptoms were headache, muscle pain, chills and joint pain, respectively.

The late-stage clinical trial for AstraZeneca's COVID-19 vaccine will be suspended in the U.S. for at least several more days, Reuters reported Monday, citing a source familiar with the matter.

"I can not say what the FDA will do", Bourla said.

A committee of outside experts - with knowledge of which individuals were given vaccine shots, is also reviewing safety data on a weekly basis and are "not notified of any safety concerns to date", Kathrin Jansen, Pfizer's head of vaccine research said during the meet.

CEO Albert Bourla says it could be distributed to Americans by end of the year.


'It is a must to release this data'.

AstraZeneca's trials resumed in the United Kingdom and Brazil on Monday following the green light from British regulators, but remain on hold in the US.

AstraZeneca's COVID-19 vaccine trials were placed on hold worldwide on September 6 after a serious side effect was reported in one volunteer in Britain. That is expected to trigger in turn an immune response so the body can fight off any future COVID-19 infection.

The first vaccines are due to be available in early 2021.

Results showed the levels of neutralizing antibodies were between 1.8 and 2.8 times greater than those seen in recovered patients.


An official the Chinese Centre for Disease Control and Prevention, Guizhen Wu, has said the coronavirus vaccines being developed in China may be ready for use by the general public as early as November, 2020.

Other reports by iNewsToday

FOLLOW OUR NEWSPAPER